{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:30:14Z","timestamp":1787045414469,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Atopic dermatitis (AD) in children differs immunologically and in barrier characteristics from adult AD, yet current severity assessment still relies heavily on clinical scoring systems with inherent subjectivity. This review summarizes advances in biomarkers associated with disease severity and persistence, as well as non-invasive detection techniques and targeted therapies. TARC\/CCL17, periostin, total IgE, and eosinophil counts show consistent utility in grading severity, whereas FLG loss-of-function mutations, VEGF, S100A8\/A9, and early skin barrier indicators are promising predictors of disease persistence and atopic march progression. Tape stripping and sebum RNA analysis enable safe, repeated monitoring in children. Despite these advances, most biomarkers still lack pediatric-specific cut-offs and large-scale validation. Future efforts should focus on establishing multi-marker panels, pediatric reference intervals, and machine learning models for endotype classification. Incorporating these tools into routine practice would facilitate early risk stratification, precise targeted treatment selection, and ultimately more personalized management of pediatric AD.<\/jats:p>","DOI":"10.3389\/fped.2026.1902799","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:53:30Z","timestamp":1787043210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric atopic dermatitis: biomarker advances in severity, persistence, and non-invasive monitoring"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhuoyuan","family":"Li","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital of Shanxi Province","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/life15030375","article-title":"Biomarkers in atopic dermatitis in children: a comprehensive review","volume":"15","author":"Indolfi","year":"2025","journal-title":"Life"},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.31083\/j.fbl2902084","article-title":"Recent advancements in the atopic dermatitis mechanism","volume":"29","author":"Savva","year":"2024","journal-title":"Front Biosci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105121","DOI":"10.1016\/j.ebiom.2024.105121","article-title":"Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review","volume":"103","author":"Park","year":"2024","journal-title":"EBioMedicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/17103568261448380","article-title":"Real-life effectiveness, safety, and growth outcomes of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis: a multicenter retrospective study from an Italian NPP program","author":"Napolitano","year":"2026","journal-title":"Dermatitis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40272-026-00747-4","article-title":"Long-term safety and efficacy of dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis","volume":"28","author":"Paller","year":"2026","journal-title":"Paediatr Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1164\/rccm.202110-2418OC","article-title":"Evolution of eczema, wheeze, and rhinitis from infancy to early adulthood: four birth cohort studies","volume":"206","author":"Haider","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jaci.2022.11.026","article-title":"Succinate and mitochondrial DNA trigger atopic march from atopic dermatitis to intestinal inflammation","volume":"151","author":"Wang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4168\/aair.2024.16.4.323","article-title":"Skin predictive biomarkers for the development of atopic dermatitis and food allergy in infants","volume":"16","author":"Kim","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.anai.2023.09.009","article-title":"Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives","volume":"132","author":"Stefanovic","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.jid.2024.12.008","article-title":"Filaggrinopathies-FLG\/FLG2: diagnostic complexities and immunotherapy","volume":"145","author":"Nouri","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/j.ajpath.2015.06.021","article-title":"Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis","volume":"185","author":"Gruber","year":"2015","journal-title":"Am J Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/jcm12041538","article-title":"The role of tight junctions in atopic dermatitis: a systematic review","volume":"12","author":"Katsarou","year":"2023","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/all.16620","article-title":"The evolution, immunopathogenesis and biomarkers of type 2 inflammation in common allergic disorders","volume":"80","author":"Gao","year":"2025","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jaci.2022.03.002","article-title":"Single-cell transcriptome profile of mouse skin undergoing antigen-driven allergic inflammation recapitulates findings in atopic dermatitis skin lesions","volume":"150","author":"Leyva-Castillo","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/all.15647","article-title":"IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis","volume":"78","author":"Maintz","year":"2023","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40257-024-00913-9","article-title":"Biomarkers in atopic dermatitis: a review of the role of IL-13 and the impact of tralokinumab treatment","volume":"26","author":"Gorelick","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.15586\/aei.v50i1.521","article-title":"Correlation between interleukin 31 and clinical manifestations in children with atopic dermatitis: an observational study","volume":"50","author":"Duca","year":"2022","journal-title":"Allergol Immunopathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2500\/aap.2020.41.190016","article-title":"Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis","volume":"41","author":"Byeon","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1442126","DOI":"10.3389\/fmicb.2024.1442126","article-title":"Changes in oral, skin, and gut microbiota in children with atopic dermatitis: a case-control study","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Microbiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1513969","DOI":"10.3389\/fped.2025.1513969","article-title":"Skin and systemic infections in children with atopic dermatitis: review of the current evidence","volume":"13","author":"Lomel\u00ed-Valdez","year":"2025","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11882-020-00937-1","article-title":"The role of new IL-1 family members (IL-36 and IL-38) in atopic dermatitis, allergic asthma, and allergic rhinitis","volume":"20","author":"Tsang","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/all.16044","article-title":"The skin microbiome in pediatric atopic dermatitis and food allergy","volume":"79","author":"Tham","year":"2024","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jdv.18178","article-title":"Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021\u2014a two-round delphi survey among international experts","volume":"36","author":"Ziehfreund","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100175","DOI":"10.1016\/j.jacig.2023.100175","article-title":"The ability of biomarkers to assess the severity of atopic dermatitis","volume":"3","author":"Nakahara","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jid.2022.10.015","article-title":"IL-4\/IL-13 inhibitors for atopic dermatitis induce psoriatic rash transcriptionally close to pustular psoriasis","volume":"143","author":"Grolleau","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1159\/000512965","article-title":"Interleukin-8 levels in the stratum corneum as a biomarker for monitoring therapeutic effect in atopic dermatitis patients","volume":"182","author":"Murata","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9689","DOI":"10.3390\/ijms26199689","article-title":"Elevated serum levels of miRNA-155 in children with atopic dermatitis: a potential biomarker of disease","volume":"26","author":"Go\u0142uchowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/all.16429","article-title":"Food allergy genetics and epigenetics: a review of genome-wide association studies","volume":"80","author":"Arnau-Soler","year":"2025","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/all.14557","article-title":"Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins","volume":"76","author":"Lauffer","year":"2021","journal-title":"Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.jaci.2024.02.018","article-title":"Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants","volume":"153","author":"Stamatas","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1367602","DOI":"10.3389\/fimmu.2024.1367602","article-title":"Screening mitochondria-related biomarkers in skin and plasma of atopic dermatitis patients by bioinformatics analysis and machine learning","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/all.15518","article-title":"Skin biomarkers predict development of atopic dermatitis in infancy","volume":"78","author":"Rinnov","year":"2023","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/all.16466","article-title":"Skin tape stripping reveals distinct biomarker profiles in chronic hand eczema of patients with and without comorbid atopic dermatitis","volume":"80","author":"Bar","year":"2025","journal-title":"Allergy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/jdv.19017","article-title":"mRNAs in skin surface lipids unveiled atopic dermatitis at 1 month","volume":"37","author":"Yamamoto-Hanada","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e13413","DOI":"10.1111\/srt.13413","article-title":"Development of a novel microneedle platform for biomarker assessment of atopic dermatitis patients","volume":"29","author":"Lee","year":"2023","journal-title":"Skin Res Technol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/1744666X.2025.2452247","article-title":"Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives","volume":"21","author":"D\u2019Auria","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s13555-024-01193-1","article-title":"Biomarkers in atopic dermatitis","volume":"14","author":"Libon","year":"2024","journal-title":"Dermatol Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/jdv.70080","article-title":"Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study","volume":"40","author":"Augustin","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1902799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:53:32Z","timestamp":1787043212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1902799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":44,"alternative-id":["10.3389\/fped.2026.1902799"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1902799","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1902799"}}